Biogen (BIIB.US) stock has been halted after the FDA has approved its controversial Alzheimer drug Aducanumab using an accelerated approval pathway. It is the first Alzheimer's treatment approved in 18 years, according to CNBC. Biogen still needs to conduct a postapproval clinical trial and FDA pointed out that the approval may be withdrawn upon unfavorable results.
Biogen (BIIB.US) stock was halted for trading at $286.10 and awaits reopening. Source: xStation5
Daily summary: Silver plunges 9% 🚨Indices, crypto and precious metals under pressure
Does the current sell-off signal the end of quantum companies?
Howmet Aerospace surges 10% after earnings reaching $100 bilion market cap 📈
US Open: Cisco Systems slides 10% after earnings 📉 Mixed sentiments on Wall Street